Compare VanEck Video Gaming and eSports ETF (ESPO) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Video Gaming and eSports ETF vs Gilead Sciences, Inc. — how do they compare? VanEck Video Gaming and eSports ETF trades at $97.07, while Gilead Sciences, Inc. trades at $136.97 (market cap $168.47B). The key difference: Gilead Sciences, Inc. pays a 2.41% dividend while VanEck Video Gaming and eSports ETF pays none, and Gilead Sciences, Inc. is trading nearer its 52-week high, VanEck Video Gaming and eSports ETF nearer its low. Which is the better fit depends on your goals.
| ESPO | GILD | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $122.30 | $155.80 |
52-Week Low | $85.25 | $110.56 |
Market Cap | — | $168.47B |
Enterprise Value | — | $191.54B |
Dividend Yield | — | 2.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ESPO trades at $97.97, down 1.64% today, with a bullish technical signal from moving averages and oscillators. Key support lies at $98, with resistance at $100. The stock shows strong momentum indicators, including a 6-day ADX of 55.42 signaling a strong trend. Recent financial data is unavailable, requiring updated SEC filings for fundamental assessment.
The outlook hinges on upcoming earnings to validate growth; risks include market volatility and lack of recent financial disclosures. Analyst sentiment is cautiously optimistic given technical strength, but fundamental clarity is needed for sustained upside.
Gilead Sciences (GILD) trades at $135.78, up 2.04% on the day, with a bullish technical signal and strong support at $134. Recent Q2 2026 earnings beat revenue estimates despite a net loss, driven by 10% base business growth from HIV drugs like Biktarvy. The company raised its full-year sales outlook, but faces a negative net income margin of -10.64% and elevated debt levels.
The outlook is mixed: robust HIV franchise growth and a 67% analyst buy rating support upside to the $151.22 consensus target, but acquisition costs, patent cliff risks, and volatile cash flows pose challenges. Investment appeal hinges on pipeline execution offsetting margin pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Video Gaming and eSports ETF
ESPO is a thematic ETF that invests in the global video gaming and eSports industry. It provides exposure to companies involved in game development, hardware, and streaming, including major firms like Tencent, Nintendo, and Electronic Arts.
Read more on ESPO →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
